# A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection

> **NCT04017962** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 102 (actual)

## Conditions studied

- CMV
- CMV Infection
- Hematopoietic Cell Transplant

## Interventions

- **DRUG:** Letermovir Pill
- **OTHER:** blood draw

## Key facts

- **NCT ID:** NCT04017962
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-19
- **Primary completion:** 2024-08-07
- **Final completion:** 2025-07-29
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2025-08-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04017962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04017962, "A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04017962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*